Welcome to our dedicated page for Shineco SEC filings (Ticker: SISI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Shineco’s breakthrough physical extraction of water-soluble phospholipids may wow scientists, but it turns every 10-K into a maze of chemistry tables and R&D footnotes. If you have ever asked, “How do I find Shineco’s clinical trial costs or nutraceutical margins without reading 300 pages?”, this page is the answer.
Stock Titan delivers AI-powered summaries that turn dense disclosures into clear insights. Our engine flags each Shineco insider trading Form 4 transactions alert, digests the entire Shineco annual report 10-K simplified, and highlights segment revenue so you can act quickly.
- Real-time push for Shineco Form 4 insider transactions real-time, including patent-related stock awards.
- Instant context around every Shineco quarterly earnings report 10-Q filing—AI pulls phospholipid yield, diagnostic reagent sales, and cash burn ratios.
- Plain-English notes on each Shineco 8-K material events explained, whether it’s FDA feedback or a nutraceutical plant expansion.
Need deeper analysis? Use our tagged excerpts to compare deferred R&D tax credits across years or to monitor Shineco executive stock transactions Form 4 before material events. The platform also links the latest Shineco proxy statement executive compensation to peer benchmarks and delivers a concise Shineco earnings report filing analysis.
Stop scrolling through EDGAR PDFs. With Stock Titan you’re understanding Shineco SEC documents with AI—from phospholipid IP disclosures to cash-flow swings—so you can focus on decisions, not data hunting.
Magnite, Inc. (MGNI) filed a Form 144 indicating a planned sale of 9,289 common shares worth approximately $204,358 at prevailing market prices. The shares were originally acquired on 02/15/2024 as restricted stock directly from the issuer and will be executed through Morgan Stanley Smith Barney LLC on or about 06/30/2025. Total shares outstanding are reported at 141,110,559, so the proposed sale represents less than 0.01 % of the float.
The filing lists David Buonasera as the selling shareholder, who has already disposed of 12,395 shares over the past three months for gross proceeds of $194,776.59. While the dollar amounts are modest relative to Magnite’s market capitalization, consecutive insider sales can raise sentiment concerns for some investors. The form contains no operational or financial performance data and makes no assertions about Magnite’s fundamentals; it solely discloses the insider’s intent to sell under Rule 144.
Shineco has completed a significant acquisition of 51% equity stake in InfiniClone Limited, a Hong Kong-based company, on June 18, 2025. The transaction structure includes:
- Cash payment of US$19,895,600
- Issuance of 3,450,000 shares of Shineco common stock
The share issuance was conducted under Regulation S, confirming the seller, Dr. Lim Kah Meng, is not a U.S. person or resident. Following the acquisition, InfiniClone becomes a direct subsidiary of Shineco Life Science Group Hong Kong, a Shineco subsidiary.
The company will file required financial statements and pro forma financial information within 71 days of this report. This strategic acquisition represents a significant expansion of Shineco's business operations in Hong Kong, with potential implications for its market presence in Asia.
Shineco, Inc. (Nasdaq: SISI) has received a Nasdaq staff determination letter indicating non-compliance with the minimum bid-price rule and faces imminent trading suspension. The notice, dated 16 June 2025, cites failure to meet the US$1.00 bid-price requirement under Nasdaq Listing Rule 5550(a)(2). Because the company already executed a reverse stock split within the past 12 months, Rule 5810(c)(3)(A)(iv) renders it ineligible for an additional 180-day grace period.
Unless Shineco appeals, Nasdaq will suspend trading on 25 June 2025 and file Form 25-NSE to remove SISI from listing and registration. The company has until 23 June 2025 to request a hearing before Nasdaq’s Hearings Panel. Shineco states it will submit the hearing request; this automatically stays the suspension and any delisting action until the panel reaches a decision or grants additional time.
The company emphasizes that its underlying operations and the ability to trade its shares on other venues are currently unaffected by the letter. However, investors face heightened liquidity and pricing risk should Nasdaq ultimately delist the shares.
FAQ
What is the current stock price of Shineco (SISI)?
What is the market cap of Shineco (SISI)?
What is the core business of Shineco Inc?
How does Shineco innovate in the extraction of phospholipids?
What markets does Shineco serve?
How does Shineco ensure product quality?
How does Shineco differentiate itself from competitors?
In what areas does Shineco apply its technological expertise?
